Compare SLG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLG | LQDA |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | United States |
| Employees | 1289 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.0B |
| IPO Year | 1997 | 2020 |
| Metric | SLG | LQDA |
|---|---|---|
| Price | $49.15 | $57.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 8 |
| Target Price | $55.65 | ★ $63.88 |
| AVG Volume (30 Days) | 1.0M | ★ 3.1M |
| Earning Date | 10-21-2026 | 11-10-2026 |
| Dividend Yield | ★ 5.07% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,046,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $379.72 |
| Revenue Next Year | N/A | $17.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.18 | ★ 1031.18 |
| 52 Week Low | $34.77 | $22.31 |
| 52 Week High | $60.09 | $93.61 |
| Indicator | SLG | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 67.76 |
| Support Level | $48.65 | $53.06 |
| Resistance Level | $49.71 | $63.46 |
| Average True Range (ATR) | 1.83 | 3.42 |
| MACD | -0.08 | 2.35 |
| Stochastic Oscillator | 11.98 | 91.35 |
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 30.6 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.